IDEC-C2B8 (Rituximab) anti-CD20 antibody treatment in relapsed advanced-stage follicular lymphomas: results of a phase-II study of the German Low-Grade Lymphoma Study Group.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples